HRP20211309T1 - N,n-bis-2-merkaptoetil izoftalamid za liječenje parkinsonove bolesti - Google Patents
N,n-bis-2-merkaptoetil izoftalamid za liječenje parkinsonove bolesti Download PDFInfo
- Publication number
- HRP20211309T1 HRP20211309T1 HRP20211309TT HRP20211309T HRP20211309T1 HR P20211309 T1 HRP20211309 T1 HR P20211309T1 HR P20211309T T HRP20211309T T HR P20211309TT HR P20211309 T HRP20211309 T HR P20211309T HR P20211309 T1 HRP20211309 T1 HR P20211309T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- parkinson
- disease
- compound
- bis
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title claims 4
- QZUPTXGVPYNUIT-UHFFFAOYSA-N isophthalamide Chemical compound NC(=O)C1=CC=CC(C(N)=O)=C1 QZUPTXGVPYNUIT-UHFFFAOYSA-N 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 238000002638 palliative care Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (5)
1. N,N-bis-2-merkaptoetil izoftalamid, ili njegova farmaceutski prihvatljiva sol, za upotrebu u liječenju Parkinsonove bolesti.
2. Spoj za upotrebu kao što je zahtjevano u zahtjevu 1, gdje pacijent također prima terapiju koja obuhvaća davanje aktivnog sastojka izabranog iz levodopa (po potrebi zajedno s inhibitorom dopamin dekarboksilaze), agonistom dopamina, MAO-B inhibitorom, amantadinom ili antikolinergičkim spojem.
3. Spoj za upotrebu kao što je zahtjevano u zahtjevu 1 ili zahtjevu 2, pri čemu je liječenje terapeutsko ili palijativno liječenje humanog pacijenta koji je obolio od Parkinsonove bolesti.
4. Spoj za upotrebu kao što je zahtjevano u bilo kojem od prethodnih zahtjeva, pri čemu liječenje ublažava jedan ili više simptoma Parkinsonove bolesti kod oboljelog pacijenta.
5. Spoj za upotrebu kao što je zahtjevano u zahtjevu 4, pri čemu simptomi uključuju Parkinsonizam.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1409662.2A GB2526623A (en) | 2014-05-30 | 2014-05-30 | New pharmaceutical use |
| EP15733860.9A EP3148588B1 (en) | 2014-05-30 | 2015-05-29 | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease |
| PCT/GB2015/051572 WO2015181567A1 (en) | 2014-05-30 | 2015-05-29 | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211309T1 true HRP20211309T1 (hr) | 2021-11-26 |
Family
ID=51214502
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230105TT HRP20230105T1 (hr) | 2014-05-30 | 2015-05-29 | N,n-bis-2-merkaptoetil izoftalamid za liječenje neurodegenerativnih bolesti |
| HRP20211309TT HRP20211309T1 (hr) | 2014-05-30 | 2021-08-13 | N,n-bis-2-merkaptoetil izoftalamid za liječenje parkinsonove bolesti |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230105TT HRP20230105T1 (hr) | 2014-05-30 | 2015-05-29 | N,n-bis-2-merkaptoetil izoftalamid za liječenje neurodegenerativnih bolesti |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20170202791A1 (hr) |
| EP (2) | EP3903774B1 (hr) |
| CY (1) | CY1124509T1 (hr) |
| DK (2) | DK3903774T3 (hr) |
| ES (2) | ES2882977T3 (hr) |
| FI (1) | FI3903774T3 (hr) |
| GB (1) | GB2526623A (hr) |
| HR (2) | HRP20230105T1 (hr) |
| HU (2) | HUE055575T2 (hr) |
| LT (2) | LT3148588T (hr) |
| MA (2) | MA40065B1 (hr) |
| PL (2) | PL3148588T3 (hr) |
| PT (2) | PT3148588T (hr) |
| RS (2) | RS63859B1 (hr) |
| SI (2) | SI3148588T1 (hr) |
| WO (1) | WO2015181567A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005057D0 (en) | 2020-04-06 | 2020-05-20 | Emeramed Ltd | New Use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586600B2 (en) | 2000-12-06 | 2003-07-01 | University Of Kentucky Research Foundation | Multidentate sulfur-containing ligands |
| US8349359B2 (en) * | 2004-11-07 | 2013-01-08 | Your Energy Systems, LLC | Liposomal formulation for oral administration of glutathione (reduced) |
| US8950583B2 (en) | 2008-12-06 | 2015-02-10 | Ermes Medical Company Limited | Method to remove heavy metals from a mammal |
| CN102612511A (zh) | 2009-09-28 | 2012-07-25 | 肯塔基大学研究基金会 | 用于从污染的环境中去除元素的含巯基化合物及其使用方法 |
| US8575218B2 (en) | 2009-09-28 | 2013-11-05 | The University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from tissues and formulations therefor |
| US8426368B2 (en) | 2010-03-25 | 2013-04-23 | The University Of Kentucky Research Foundation | Method of ameliorating oxidative stress and supplementing the diet |
| US20110237776A1 (en) | 2010-03-25 | 2011-09-29 | Haley Boyd E | Aromatic compounds with sulfur containing ligands |
-
2014
- 2014-05-30 GB GB1409662.2A patent/GB2526623A/en not_active Withdrawn
-
2015
- 2015-05-29 RS RS20221189A patent/RS63859B1/sr unknown
- 2015-05-29 SI SI201531710T patent/SI3148588T1/sl unknown
- 2015-05-29 ES ES15733860T patent/ES2882977T3/es active Active
- 2015-05-29 LT LTEPPCT/GB2015/051572T patent/LT3148588T/lt unknown
- 2015-05-29 SI SI201531911T patent/SI3903774T1/sl unknown
- 2015-05-29 RS RS20210852A patent/RS62095B1/sr unknown
- 2015-05-29 PT PT157338609T patent/PT3148588T/pt unknown
- 2015-05-29 LT LTEP21180847.2T patent/LT3903774T/lt unknown
- 2015-05-29 EP EP21180847.2A patent/EP3903774B1/en active Active
- 2015-05-29 HU HUE15733860A patent/HUE055575T2/hu unknown
- 2015-05-29 PL PL15733860T patent/PL3148588T3/pl unknown
- 2015-05-29 HR HRP20230105TT patent/HRP20230105T1/hr unknown
- 2015-05-29 HU HUE21180847A patent/HUE060927T2/hu unknown
- 2015-05-29 DK DK21180847.2T patent/DK3903774T3/da active
- 2015-05-29 MA MA40065A patent/MA40065B1/fr unknown
- 2015-05-29 US US15/313,877 patent/US20170202791A1/en not_active Abandoned
- 2015-05-29 PT PT211808472T patent/PT3903774T/pt unknown
- 2015-05-29 DK DK15733860.9T patent/DK3148588T3/da active
- 2015-05-29 FI FIEP21180847.2T patent/FI3903774T3/fi active
- 2015-05-29 EP EP15733860.9A patent/EP3148588B1/en active Active
- 2015-05-29 ES ES21180847T patent/ES2938080T3/es active Active
- 2015-05-29 PL PL21180847.2T patent/PL3903774T3/pl unknown
- 2015-05-29 WO PCT/GB2015/051572 patent/WO2015181567A1/en active Application Filing
-
2017
- 2017-11-22 US US15/821,371 patent/US20180250247A1/en not_active Abandoned
-
2020
- 2020-02-06 MA MA54630A patent/MA54630B1/fr unknown
-
2021
- 2021-08-13 HR HRP20211309TT patent/HRP20211309T1/hr unknown
- 2021-09-07 CY CY20211100788T patent/CY1124509T1/el unknown
- 2021-12-22 US US17/558,975 patent/US20220287994A1/en active Pending
-
2022
- 2022-09-27 US US17/953,622 patent/US11628151B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015020453A2 (pt) | formas de dosagem de liberação prolongada orais de tofacitinibe | |
| PH12015502628A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| JP2017514871A5 (hr) | ||
| MX2017003102A (es) | Formulacion para inhalacion liquida que comprende rpl554. | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| MD3416631T2 (ro) | Agenți terapeutici pentru bolile neurodegenerative | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| HRP20211309T1 (hr) | N,n-bis-2-merkaptoetil izoftalamid za liječenje parkinsonove bolesti | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| PH12019501785A1 (en) | Intranasal composition comprising betahistine | |
| BR112015018895A2 (pt) | composição farmacêutica multiparticulada compreendendo uma multiplicidade de dois tipos de pelotas | |
| ZA201905309B (en) | Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals | |
| CL2015003679A1 (es) | Agentes terapéuticos para el uso en la profilaxis y/o el tratamiento de trastornos del movimiento hiperquineticoico | |
| PH12016501975A1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| PH12018500221A1 (en) | A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps) | |
| EA201891911A1 (ru) | Применение тамоксифена для лечения кистозного фиброза у пациентов обоих полов | |
| EA201991384A1 (ru) | Комбинации диклофенака и антагонистов h2-рецептора для лечения боли и воспаления | |
| ITUB20153076A1 (it) | Composti farmaceuticamente attivi per l?impiego nel trattamento terapeutico di disturbi del movimento. | |
| RU2014104644A (ru) | Способ повышения эффективности лечения коров, больных острым гнойно-катаральным эндометритом | |
| TH167850B (th) | (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค | |
| TH167851B (th) | (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค |